SecBot SecBot
8-K ·Filed May 7, 2026
RC

RCKTW

ROCKET PHARMACEUTICALS, INC.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001140361-26-019573
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The KRESLADI approval and PRV monetization remove near-term financing risk and de-risk the pipeline; watch for Danon disease program update in H2 2026 as next major catalyst. Market cap of $1M for the warrant (RCKTW) means price swings can be extreme on low volume.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.0193
T+0 close · May 7, 2026 · via day close
Latest settled
−90.67%
T+60 · $0.001800
Vs SPY
−95.51%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $0.0193entry
  2. T+1 · 6mo ago 0.00%α −0.23% · $0.0193
  3. T+5 · 6mo ago 0.00%α −1.46% · $0.0193
  4. T+20 · 5mo ago 0.00%α −0.02% · $0.0193
  5. T+60 · 3mo ago −90.67%α −95.51% · $0.001800

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rocket Pharmaceuticals reported Q1 2026 net loss of -$47.6M (-$0.42/share), improving from -$61.3M (-$0.56) a year ago. The key catalyst was FDA accelerated approval of KRESLADI for severe LAD-I in March, followed by monetization of the resulting Rare Pediatric Disease Priority Review Voucher for $180M in April, extending cash runway into Q2 2028. The Danon disease pivotal Phase 2 trial has resumed dosing; an update is expected in H2 2026.

Key Financial Metrics

EPS
−$0.42
Rating
in line

Key Facts

  • FDA granted accelerated approval for KRESLADI in severe LAD-I (March 2026)
  • PRV sold for $180M on April 28, 2026 (non-dilutive capital)
  • Pro forma cash ~$322.6M (including PRV proceeds); runway into Q2 2028
  • Q1 2026 net loss -$47.6M (-$0.42/share) vs -$61.3M (-$0.56) YoY
  • Danon disease Phase 2 trial dosing resumed; program update in H2 2026
  • No revenue reported (pre-commercial stage)
  • 109.1M shares outstanding as of March 31, 2026

Financial Impact

PRV sale adds $180M cash; net loss improved by $13.7M YoY; cash burn reduction extends runway 4+ quarters

cashnet losscash runway

Risk Factors

  • No commercial revenue yet; KRESLADI launch uptake uncertain
  • Danon disease Phase 2 results could disappoint
  • Additional clinical holds or safety signals in AAV programs
  • Dilution risk from future equity raises (though cash extended)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-019573
Document: ef20072739_8k.htm0001140361-26-019573
Document: 0001140361-26-019573-index-headers.html0001140361-26-019573
Document: 0001140361-26-019573-index.html0001140361-26-019573
Document: 0001140361-26-019573.txt0001140361-26-019573
8-K Data (Synthetic)0001140361-26-019573

Track record

4 reports on RCKTW

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. May 13, 202626w ago 144 Neutral 2/10 Entry $0.0193 No price data
  2. May 7, 202627w ago 8-K Mixed 6/10 Viewing Entry $0.0193 to $0.001800 ▼ −90.67% −95.51% vs SPY
  3. May 7, 202627w ago 144 Neutral 3/10 Entry $0.0193 to $0.003200 ▼ −83.42% −87.25% vs SPY
  4. Apr 28, 202628w ago 8-K Bullish 8/10 Entry $0.0193 to $0.002700 ▼ −86.01% −90.00% vs SPY
Showing 4 of 4

US Market Status

Market Closed · Opens in 6h 24m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026